To sum up, evidence has shown that the five genes clarified in this work all have essential roles in malignant development, indicating that developing corresponding targeted therapies for high-risk DOCK2-mutant HCC was feasible. This evidence concerns the gene DOCK2 and hepatocellular carcinoma.